Neurocrine Biosciences (NBIX) Receivables - Other (2019 - 2025)
Neurocrine Biosciences (NBIX) has disclosed Receivables - Other for 6 consecutive years, with $20.5 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Other rose 42.36% year-over-year to $20.5 million, compared with a TTM value of $20.5 million through Dec 2025, up 42.36%, and an annual FY2025 reading of $20.5 million, up 42.36% over the prior year.
- Receivables - Other was $20.5 million for Q4 2025 at Neurocrine Biosciences, up from $14.4 million in the prior quarter.
- Across five years, Receivables - Other topped out at $20.5 million in Q4 2025 and bottomed at $2.7 million in Q2 2021.
- Average Receivables - Other over 4 years is $8.5 million, with a median of $6.8 million recorded in 2023.
- The sharpest move saw Receivables - Other plummeted 31.91% in 2021, then surged 186.36% in 2024.
- Year by year, Receivables - Other stood at $2.8 million in 2021, then soared by 300.0% to $11.2 million in 2023, then rose by 28.57% to $14.4 million in 2024, then surged by 42.36% to $20.5 million in 2025.
- Business Quant data shows Receivables - Other for NBIX at $20.5 million in Q4 2025, $14.4 million in Q4 2024, and $12.6 million in Q1 2024.